Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy

achieved a superior antitumor effect when combined with PD-1 blockade, suggesting the complementarity between the two treatment modalities. Overall, this work provides promising lead compounds for the clinical development of HPK1 PROTACs as small-molecule therapeutics in tumor immunotherapy.